---
title: "Citi Sticks to Their Hold Rating for GlaxoSmithKline (GSK)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294160582.md"
description: "Citi analyst Graham Parry maintained a Hold rating on GlaxoSmithKline (GSK) with a £21.00 price target. This follows a similar Hold from Deutsche Bank, while Bernstein recently kept a Buy rating on the stock."
datetime: "2026-07-29T06:05:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294160582.md)
  - [en](https://longbridge.com/en/news/294160582.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294160582.md)
generator: "portal-rs"
---

# Citi Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

Citi analyst Graham Parry maintained a Hold rating on GlaxoSmithKline today and set a price target of £21.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Parry is a 2-star analyst with an average return of 0.7% and a 59.50% success rate.

In addition to Citi, GlaxoSmithKline also received a Hold from Deutsche Bank ‘s Emmanuel Papadakis in a report issued on July 27. However, yesterday, Bernstein maintained a Buy rating on GlaxoSmithKline (LSE: GSK).

### Related Stocks

- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [DB.US](https://longbridge.com/en/quote/DB.US.md)
- [AB.US](https://longbridge.com/en/quote/AB.US.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)
- [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md)
- [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md)
- [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md)

## Related News & Research

- [Berenberg Bank Keeps Their Hold Rating on GlaxoSmithKline (GSK)](https://longbridge.com/en/news/296063100.md)
- [REG - GSK PLC - Director/PDMR Shareholding](https://longbridge.com/en/news/296244146.md)
- [Chugai licenses anti-dengue antibody AID351 to GSK in exclusive deal](https://longbridge.com/en/news/296167792.md)
- [Bernstein Reaffirms Their Buy Rating on GlaxoSmithKline (GSK)](https://longbridge.com/en/news/294085968.md)
- [GSK: Hold Rating Reaffirmed as Near-Term Strength Offsets Long-Term Uncertainties; 2,350p Price Target Maintained](https://longbridge.com/en/news/294183934.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**